These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18617577)

  • 41. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
    Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
    Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acromegaly.
    Chanson P; Salenave S; Kamenicky P
    Handb Clin Neurol; 2014; 124():197-219. PubMed ID: 25248589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pregnancy in acromegaly patients treated with pegvisomant.
    van der Lely AJ; Gomez R; Heissler JF; Åkerblad AC; Jönsson P; Camacho-Hübner C; Kołtowska-Häggström M
    Endocrine; 2015 Aug; 49(3):769-73. PubMed ID: 25542184
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pegvisomant: new preparation. A last resort in acromegaly.
    Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegvisomant Pfizer/Sensus.
    Goffin V; Touraine P
    Curr Opin Investig Drugs; 2004 Apr; 5(4):463-8. PubMed ID: 15134290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer.
    Ross RJ; Leung KC; Maamra M; Bennett W; Doyle N; Waters MJ; Ho KK
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1716-23. PubMed ID: 11297608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimal use of pegvisomant in acromegaly: are we getting there?
    Giustina A
    Endocrine; 2015 Feb; 48(1):3-8. PubMed ID: 25348149
    [No Abstract]   [Full Text] [Related]  

  • 50. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY.
    Bernabeu I; Pico A; Venegas E; Aller J; Alvarez-Escolá C; García-Arnés JA; Marazuela M; Jonsson P; Mir N; García Vargas M;
    Pituitary; 2016 Apr; 19(2):127-37. PubMed ID: 26553421
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with site-specific PEG conjugates.
    Basu R; Brody R; Sandbhor U; Kulkarni P; Davis E; Swegan D; Caggiano LJ; Brenya E; Neggers S; Kopchick JJ
    J Biol Chem; 2023 Aug; 299(8):105030. PubMed ID: 37442239
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pegvisomant: structure and function.
    Pradhananga S; Wilkinson I; Ross RJ
    J Mol Endocrinol; 2002 Aug; 29(1):11-4. PubMed ID: 12200225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The nuclear-localized GHR is involved in the cell proliferation of gastric cancer, and pegvisomant may be an important potential drug to inhibit the proliferation of gastric cancer cells.
    Meng Y; Zhou B; Pei Z; Chen Y; Chang D
    Biochem Cell Biol; 2022 Apr; 100(2):125-135. PubMed ID: 35061546
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Growth hormone receptor antagonists: discovery and potential uses.
    Kopchick JJ; Okada S
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S103-9. PubMed ID: 11527080
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and mechanism of action of pegvisomant.
    Kopchick JJ
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S21-5. PubMed ID: 12670297
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pituitary gigantism treated successfully with the growth hormone receptor antagonist, pegvisomant.
    Daniel A; d'Emden M; Duncan E
    Intern Med J; 2013 Mar; 43(3):345-7. PubMed ID: 23441666
    [No Abstract]   [Full Text] [Related]  

  • 57. Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.
    Maffei P; Martini C; Pagano C; Sicolo N; Corbetti F
    Ann Intern Med; 2006 Aug; 145(4):310-2. PubMed ID: 16908925
    [No Abstract]   [Full Text] [Related]  

  • 58. Automated 22-kD growth hormone-specific assay without interference from Pegvisomant.
    Manolopoulou J; Alami Y; Petersenn S; Schopohl J; Wu Z; Strasburger CJ; Bidlingmaier M
    Clin Chem; 2012 Oct; 58(10):1446-56. PubMed ID: 22908135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medical treatment of acromegaly in pregnancy, highlights on new reports.
    Fleseriu M
    Endocrine; 2015 Aug; 49(3):577-9. PubMed ID: 25931411
    [No Abstract]   [Full Text] [Related]  

  • 60. Growth Hormone Signaling in Liver Diseases: Therapeutic Potentials and Controversies.
    Oxley M; Francis H; Sato K
    Semin Liver Dis; 2023 Feb; 43(1):24-30. PubMed ID: 36652958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.